SHR-1209

Phase 2UNKNOWN

0 views this week 0 watching💤 Quiet

Interest: 31/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Familial Hypercholesterolemia

Conditions

Familial Hypercholesterolemia

Trial Timeline

Sep 1, 2020 → Aug 31, 2021

NCT ID

NCT04455581

About SHR-1209

SHR-1209 is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for Familial Hypercholesterolemia. The current trial status is unknown. This product is registered under clinical trial identifier NCT04455581. Target conditions include Familial Hypercholesterolemia.

What happened to similar drugs?

5 of 20 similar drugs in Familial Hypercholesterolemia were approved

Approved (5) Terminated (3) Active (14)

✅EvolocumabAmgenApproved

✅evolocumabAmgenApproved

✅AnakinraSwedish Orphan BiovitrumApproved

✅Colesevelam hydrochloride film-coated tablets + PlaceboSanofiApproved

✅PraluentSanofiApproved

🔄SHR-1209 ;placebo + SHR-1209 ;placebo + SHR-1209 ;placeboJiangsu Hengrui MedicinePhase 3

🔄Rosuvastatin 20mg + PlaceboAstraZenecaPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05370950	Phase 1	Completed	May 25, 2022	Dec 31, 2022	Hypercholesterolemia and Hyperlipidemia
NCT04455581	Phase 2	UNKNOWN	Sep 1, 2020	Aug 31, 2021	Familial Hypercholesterolemia

Competing Products

20 competing products in Familial Hypercholesterolemia

See all competitors

Product	Company	Stage	Hype Score
Bromocriptine Mesilate + Placebos	Towa Pharmaceutical	Phase 1/2	32
SHR-1209 ;placebo + SHR-1209 ;placebo + SHR-1209 ;placebo	Jiangsu Hengrui Medicine	Phase 3	40
Rosuvastatin 20mg + Placebo	AstraZeneca	Phase 3	40
rosuvastatin calcium + rosuvastatin calcium + rosuvastatin calcium	AstraZeneca	Phase 3	40
Rosuvastatin + Placebo	AstraZeneca	Phase 3	40
Rosuvastatin 20mg	AstraZeneca	Phase 3	40
AZD0780 + Placebo	AstraZeneca	Phase 3	44
Anacetrapib + Placebo for anacetrapib	Merck	Phase 3	40
Statins and Ezetimibe	Merck	Pre-clinical	22
Comparator: niacin (+) laropiprant (MK0524A) + Comparator: placebo	Merck	Phase 3	32
MK-0524A + MK-0524A	Merck	Phase 1	21
Enlicitide Decanoate + Placebo	Merck	Phase 2/3	45
Inclisiran + Placebo	Novartis	Phase 3	40
DFV890	Novartis	Phase 2	35
Canakinumab	Novartis	Phase 2	35
Inclisiran Sodium for injection + Placebo + Placebos	Novartis	Phase 3	40
LCQ908 + Placebo	Novartis	Phase 3	40
Inclisiran	Novartis	Phase 3	44
Inclisiran + Placebo	Novartis	Phase 3	40
Fluvastatin	Novartis	Phase 3	40